Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. HOOD
10. IBM

Go back to Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

February 25, 2021 7:54 AM EST

Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.55), $0.09 worse than the analyst estimate of ($0.46).

2020 was a pivotal year for Kala, highlighted by U.S. Food and Drug Administration (FDA) approval of EYSUVIS, the first and only prescription therapy specifically for the... More